Researchers argue for a shift away from a focus on antipsychotic adherence toward understanding service users’ diverse patterns of use.
The CHR-P model focuses on “attenuated psychosis” to predict “transition” to schizophrenia and ignores other factors. But new research shows that the model is a poor predictor.
Researchers push for a renewed focus on true shared decision-making for patients diagnosed with psychosis.
Researchers have found further evidence that the anticholinergic effect of psychiatric drugs can lead to cognitive impairments.
Qualitative study finds that both internal resources and systemic factors play a role in antipsychotic discontinuation outcomes.
The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.
People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.
Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.
The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.
A new study finds that anticholinergic drugs, like antidepressants and antipsychotics, are associated with mild cognitive decline.
A new study finds that adding an antipsychotic to existing antidepressant treatment is associated with a 45% increased risk of early death.
A new study finds adverse long-term consequences associated with the increased use of antipsychotics in first-episode psychosis.
An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.
A new study has found a strong association between antipsychotic drugs and higher rates of severe cases of COVID-19.
Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.
A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.
Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.
A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.
New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.
A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.
A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.
The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.
There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.
The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.